Ghent University Academic Bibliography

Advanced

CGRP antagonists: hope for a new era in acute migraine treatment

CAROLINE SCHELSTRAETE UGent and Koen Paemeleire UGent (2009) ACTA NEUROLOGICA BELGICA. 109(4). p.252-261
abstract
Calcitonin gene-related peptide (CGRP) has a widespread distribution throughout the trigeminovascular system and other brain areas involved in migraine pathogenesis. Serum levels of CGRP are elevated during the migraine attack and return to normal with alleviation of pain. Intravenous injection of CGRP in migraineurs results in delayed headache similar to migraine. Since CGRP receptor antagonists lack direct vasoconstrictor activity, this therapeutic approach may offer advantages over the current mainstay of specific acute migraine treatment with 5-HT1B/1D receptor agonists (triptans), contra-indicated in patients with underlying cardiovascular disease. Intravenous BIBN4096BS (olcegepant) and oral MK-0974 (telcagepant), two CGRP-receptor antagonists, were safe and effective in the treatment of migraine attacks hi Phase I and II trials. In a Phase III clinical trial, the efficacy of telcagepant 300 mg was comparable to that of zolmitriptan 5 mg. We intend to review the rationale for the use of CGRP-receptor antagonists, and to outline current developments and future perspectives.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
TRIGEMINOVASCULAR SYSTEM, CLUSTER HEADACHE, RECEPTOR ANTAGONIST, CALCITONIN-GENE, CORONARY-ARTERY STENOSIS, GENE-RELATED PEPTIDE, trigeminovascular system, CGRP-antagonists, migraine, calcitonin-gene related peptide, Neuropeptides, PHARMACOLOGICAL CHARACTERIZATION, POTENT VASODILATOR, EXTRACEREBRAL CIRCULATION, NEUROPEPTIDE CHANGES
journal title
ACTA NEUROLOGICA BELGICA
Acta Neurol. Belg.
volume
109
issue
4
pages
252 - 261
Web of Science type
Review
Web of Science id
000273736400002
JCR category
CLINICAL NEUROLOGY
JCR impact factor
0.597 (2009)
JCR rank
147/165 (2009)
JCR quartile
4 (2009)
ISSN
0300-9009
language
English
UGent publication?
yes
classification
A1
id
858360
handle
http://hdl.handle.net/1854/LU-858360
date created
2010-02-10 17:45:57
date last changed
2012-11-07 09:50:26
@article{858360,
  abstract     = {Calcitonin gene-related peptide (CGRP) has a widespread distribution throughout the trigeminovascular system and other brain areas involved in migraine pathogenesis. Serum levels of CGRP are elevated during the migraine attack and return to normal with alleviation of pain. Intravenous injection of CGRP in migraineurs results in delayed headache similar to migraine. Since CGRP receptor antagonists lack direct vasoconstrictor activity, this therapeutic approach may offer advantages over the current mainstay of specific acute migraine treatment with 5-HT1B/1D receptor agonists (triptans), contra-indicated in patients with underlying cardiovascular disease. Intravenous BIBN4096BS (olcegepant) and oral MK-0974 (telcagepant), two CGRP-receptor antagonists, were safe and effective in the treatment of migraine attacks hi Phase I and II trials. In a Phase III clinical trial, the efficacy of telcagepant 300 mg was comparable to that of zolmitriptan 5 mg. We intend to review the rationale for the use of CGRP-receptor antagonists, and to outline current developments and future perspectives.},
  author       = {SCHELSTRAETE, CAROLINE and Paemeleire, Koen},
  issn         = {0300-9009},
  journal      = {ACTA NEUROLOGICA BELGICA},
  keyword      = {TRIGEMINOVASCULAR SYSTEM,CLUSTER HEADACHE,RECEPTOR ANTAGONIST,CALCITONIN-GENE,CORONARY-ARTERY STENOSIS,GENE-RELATED PEPTIDE,trigeminovascular system,CGRP-antagonists,migraine,calcitonin-gene related peptide,Neuropeptides,PHARMACOLOGICAL CHARACTERIZATION,POTENT VASODILATOR,EXTRACEREBRAL CIRCULATION,NEUROPEPTIDE CHANGES},
  language     = {eng},
  number       = {4},
  pages        = {252--261},
  title        = {CGRP antagonists: hope for a new era in acute migraine treatment},
  volume       = {109},
  year         = {2009},
}

Chicago
SCHELSTRAETE, CAROLINE, and Koen Paemeleire. 2009. “CGRP Antagonists: Hope for a New Era in Acute Migraine Treatment.” Acta Neurologica Belgica 109 (4): 252–261.
APA
SCHELSTRAETE, C., & Paemeleire, K. (2009). CGRP antagonists: hope for a new era in acute migraine treatment. ACTA NEUROLOGICA BELGICA, 109(4), 252–261.
Vancouver
1.
SCHELSTRAETE C, Paemeleire K. CGRP antagonists: hope for a new era in acute migraine treatment. ACTA NEUROLOGICA BELGICA. 2009;109(4):252–61.
MLA
SCHELSTRAETE, CAROLINE, and Koen Paemeleire. “CGRP Antagonists: Hope for a New Era in Acute Migraine Treatment.” ACTA NEUROLOGICA BELGICA 109.4 (2009): 252–261. Print.